HORIZON THERAPEUTICS USA, INC. (FORMERLY HORIZON PHARMA USA, INC.)

Lobbying Spend

—

Filings

Firms Hired

Active Period

2016–2023

Lobbying Spend by Year

Client-reported lobbying expenses on LDA filings

Year	Lobbying Spend	Filings	Firms
2023	—	4	1
2022	—	4	1
2021	—	4	1
2020	—	4	1
2019	—	4	1
2018	—	4	1
2017	—	4	1
2016	—	1	1

Lobbying firms retained by this client; amounts are client-reported expenses when available

Firm Name	Reported Spend	Filings
COVINGTON & BURLING LLP	—	29

Government entities explicitly identified as targets in LDA filings

Most frequently reported lobbying issues

Issue Code	Description	Reports
Medicare/Medicaid	Medicare/Medicaid	29
Taxation/Internal Revenue Code	Taxation/Internal Revenue Code	11
Health Issues	Health Issues	5
Copyright/Patent/Trademark	Copyright/Patent/Trademark	1
Budget/Appropriations	Budget/Appropriations	1
Medical/Disease Research/Clinical Labs	Medical/Disease Research/Clinical Labs	1

Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded

H.R. 2163117th Congress

Safe Step Act

2022 · fourth_quarter · Firm: COVINGTON & BURLING LLP

Cited source text and reported amounts

Drug pricing policies, including H.R. 2163, The Safe Step Act.

Client expense: — · Firm income: $60,000

Matched citations: H.R. 2163

HORIZON THERAPEUTICS USA, INC. (FORMERLY HORIZON PHARMA USA, INC.) — Lobbying Disclosure | Poliscope